Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours.

#1251

Introduction: Despite advances, detection and quantification of NET activity by imaging remains a challenge.

Aim(s): We present the first in-man study of 18F-fluoroethyl triazole [Tyr3] octreotate (18F-FET-βAG TOCA) in NET patients to evaluate biodistribution, dosimetry and safety.

Materials and methods: 18F-FET-βAG TOCA was synthesized via the click reaction. Nine patients were enrolled into study. Eight patients with sporadic NET and 1 MEN1 syndrome. Mean age 56 yr (range 35-73 yr) and weight 75.2kg (91.2-66.3 kg).Patients underwent whole body PET-CT multi-bed scanning over 4h and venous blood samples were taken at specific intervals to measure 18F radioactivity concentration in blood and plasma. Regions of interest were drawn, to derive individual and mean organ residence times; effective dose (ED) was calculated with OLINDA 1.1

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: DUBASH S

Authors: Dubash S, Keat N, Mapelli P, Twyman F, Carroll L,

Keywords: PET,